Zalukast 20 mg
Zafirlukast
Category: Tablet
Manufacturer: Alco Pharma Limited
Allopathic
MFG. Licence No. Biological
193
MFG. Licence No. Non-Biological
430
Address
House No. 3/B, Plot No. 33, Section-7, Mirpur, Dha
Medicine Selling service is not available yet.
Related Medicines
Uses of Zalukast:
- Asthma prevention
Chronic asthma
Hypersensitivity, hepatic impairment, cirrhosis, acute asthmatic attacks. Lactation.
Leukotriene receptor antagonists
Zafirlukast is a selective and competitive leukotriene-receptor antagonist (LTRA) of leukotriene D4 and E4 (LTD4 and LTE4), components of slow-reacting substance of anaphylaxis (SRSA). Cysteinyl leukotriene production and receptor occupation have been correlated with the pathophysiology of asthma, including airway oedema, smooth muscle constriction, and altered cellular activity associated with the inflammatory process, which contribute to the signs and symptoms of asthma.
How to use
Zafirlukast:
Take this medicine in the dose and duration as advised by your doctor. Swallow it as a whole. Do not chew, crush or break it.
Zafirlukast is to be taken empty stomach.
Administration:
Should be taken on an empty stomach. Take at least 1 hr before or 2 hr after meals.
Adult Dose:
Oral
Chronic asthma
Adult: 20 mg bid.
Hepatic impairment: Contraindicated.
Child Dose:
Oral
Chronic asthma
Child: 5-11 yr: 10 mg bid.
>12 yr: 20 mg bid.
Renal Dose:
Renal Impairment
Dose adjustment not necessary
May enhance anticoagulant activity of warfarin resulting to increased prothrombin time. Decreased plasma levels w/ theophylline, terfenadine and erythromycin. Increased plasma levels w/ fluconazole and high dose aspirin.
Hypersensitivity, hepatic impairment, cirrhosis, acute asthmatic attacks. Lactation.
Common
- Headache
- Infection
- Nausea
- Diarrhea
- Pain
- Weakness
>10%
headache (12.9% in age >12 yr)
1-10%
Abdominal pain (1.8%),Infection (3.5%),Nausea (3.1%),Diarrhea (2.8%),Generalized pain (1.8%),Vomiting (1.5%),Dyspepsia/gastritits (1.3%),Increased ALT (1.5%),Infection (4%),Back pain (2%),Weakness (2%),Myalgia (2%)
Frequency Not Defined
Eosinophilia
Eosinophilic pneumonia
Vasculitis
Malaise
Bleeding
Bruising
Potentially Fatal: Severe hepatotoxicity.
Pregnancy: The safety of Zafirlukast in human pregnancy has not been established. In animal studies, Zafirlukast did not have any apparent effect on fertility and did not appear to have any teratogenic or selective toxic effect on the foetus. The potential risks should be weighed against the benefits of continuing therapy during pregnancy and Zafirlukast should be used during pregnancy only if clearly needed.Lactation: Zafirlukast is excreted in human breast milk. Zafirlukast should not be administered to nursing mothers.
Precaution:
Not indicated for use in the reversal of bronchospasm in acute asthma attacks. Avoid abrupt substitution to oral or inhaled corticosteroids. Renal impairment. Pregnancy and lactation. Monitoring Parameters Monitor for improvements in air flow; monitor closely for sign/symptoms of hepatic injury; periodic monitoring of LFTs.
Lactation: Excreted in breast milk; not recommended
Store between 20-25° C. Protect from light and moisture.
Zafirlukast selectively antagonises the leukotriene D4 receptor. It inhibits bronchoconstriction caused by various inhaled antigens or irritants. It is not used in acute asthma attacks.
Samm Care